Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,604 Million (Large Cap)
80.00
NA
0.25%
-0.54
9.46%
6.53
Revenue and Profits:
Net Sales:
142 Million
(Quarterly Results - Sep 2025)
Net Profit:
42 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
80.41%
0%
80.41%
6 Months
107.37%
0%
107.37%
1 Year
156.8%
0%
156.8%
2 Years
80.08%
0%
80.08%
3 Years
104.52%
0%
104.52%
4 Years
-0.23%
0%
-0.23%
5 Years
-42.48%
0%
-42.48%
HitGen, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.43%
EBIT Growth (5y)
16.40%
EBIT to Interest (avg)
5.08
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.56
Sales to Capital Employed (avg)
0.26
Tax Ratio
19.51%
Dividend Payout Ratio
46.66%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.70%
ROE (avg)
4.35%
Valuation key factors
Factor
Value
P/E Ratio
80
Industry P/E
Price to Book Value
6.72
EV to EBIT
91.16
EV to EBITDA
55.98
EV to Capital Employed
13.33
EV to Sales
19.29
PEG Ratio
0.77
Dividend Yield
0.25%
ROCE (Latest)
14.62%
ROE (Latest)
8.36%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
142.40
103.50
37.58%
Operating Profit (PBDIT) excl Other Income
40.30
26.30
53.23%
Interest
3.50
3.30
6.06%
Exceptional Items
3.30
-0.10
3,400.00%
Consolidate Net Profit
42.20
19.40
117.53%
Operating Profit Margin (Excl OI)
283.40%
119.00%
16.44%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 37.58% vs 14.87% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 117.53% vs 55.20% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
427.00
367.50
16.19%
Operating Profit (PBDIT) excl Other Income
116.60
60.10
94.01%
Interest
13.10
13.20
-0.76%
Exceptional Items
-38.70
-14.30
-170.63%
Consolidate Net Profit
49.90
40.90
22.00%
Operating Profit Margin (Excl OI)
142.40%
16.40%
12.60%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 16.19% vs 11.53% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 22.00% vs 60.39% in Dec 2023
About HitGen, Inc. 
HitGen, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






